Olanzapine of children, adolescents, and treatment adults with pervasive developmental disorders: An open-label pilot study

Journal of Clinical Psychopharmacology

Volumn 19, Issue 1, 1999, Pages 37-44

  Potenza, Marc N ^a,b   Holmes, Janice P ^a,b   Kanes, Stephen J ^a,b   Mcdougle, Christopher J ^c  

^a Yale University School of Medicine   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NEUROLEPTIC AGENT; OLANZAPINE; BENZODIAZEPINE DERIVATIVE; DRUG DERIVATIVE; PIRENZEPINE;

ADOLESCENT; ADULT; APPETITE DISORDER; ARTICLE; AUTISM; BODY WEIGHT DISORDER; CHILD; CLINICAL ARTICLE; DEVELOPMENTAL DISORDER; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HUMAN; MALE; PILOT STUDY; PRIORITY JOURNAL; ANALYSIS OF VARIANCE; CLINICAL TRIAL; DRUG EFFECT; OUTCOME ASSESSMENT; PRESCHOOL CHILD; PSYCHOMOTOR PERFORMANCE; TREATMENT OUTCOME;

ADOLESCENT; ADULT; ANALYSIS OF VARIANCE; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; CHILD; CHILD DEVELOPMENT DISORDERS, PERVASIVE; CHILD, PRESCHOOL; FEMALE; HUMANS; MALE; OUTCOME ASSESSMENT (HEALTH CARE); PILOT PROJECTS; PIRENZEPINE; PSYCHOMOTOR PERFORMANCE; TREATMENT OUTCOME;

EID: 0033071543     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004714-199902000-00008     Document Type: Article

References (70)

1. McDougle CJ. Psychopharmacology. In: Cohen DJ, Volkmar FR, eds. Handbook of autism and pervasive developmental disorders. 2nd ed. New York: John Wiley & Sons, 1997:707-29.
2. Cook EH. Autism: review of neurochemical investigation. Synapse 1990;6:292-308.
3. Ritvo ER, Freeman BJ, Yuwiler A, Geller E, Schroth P, Yokota A, Mason-Brothers A, August GJ, Klykylo W, Leventhal B, Lewis K, Piggott L, Realmuto G, Stubbs EG, Umansky R. Fenfluramine treatment of autism: UCLA collaborative study of 81 patients at nine medical centers. Psychopharmacol Bull 1986;22:133-40.
4. Ekman G, Miranda-Linné F, Gillberg C, Garle M, Wetterberg L. Fenfluramide treatment of twenty children with autism. J Autism Dev Disord 1989;19:511-32.
5. Sherman J, Factor DC, Swinson R, Darjes RW. The effects of fenfluramine (hydrochloride) on the behaviors of fifteen autistic children. J Autism Dev Disord 1989;19:533-43.
6. Schuster CR, Lewis M, Seiden LS. Fenfluramine: neurotoxicity. Psychopharmacol Bull 1986;22:148-51.
7. Connolly HM, Crary JL, McGoon MD, Hensrud DD, Edwards BS, Edwards WD, Schaff HV. Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med 1997;337:581-8.
8. Realmuto GM, August GJ, Garfinkel BD. Clinical effect of buspirone in autistic children. J Clin Psychopharmacol 1989;9:122-5.
9. Ratey JJ, Sovner R, Mikkelsen E, Chmielinski HE. Buspirone therapy for maladaptive behavior and anxiety in developmentally disabled persons. J Clin Psychiatry 1989;50:382-4.
10. Gedye A. Buspirone alone or with serotonergic diet reduced aggression in a developmentally disabled adult. Biol Psychiatry 1990;30:88-91.
11. Ricketts RW, Goza AB, Ellis CR, Singh YN, Chambers S, Singh NN, Cooke JC. Clinical effects of buspirone on intractable self-injury in adults with mental retardation. J Am Acad Child Adolesc Psychiatry 1994;33:270-6.
12. Ratey J, Sovner R, Parks A, Rogentine K. Buspirone treatment of aggression and anxiety in mentally retarded patients: a multiple baseline, placebo lead-in study. J Clin Psychiatry 1991;52:159-62.
13. Gedye A. Trazodone reduced aggressive and self-injurious movements in a mentally handicapped male patient with autism. J Clin Psychopharmacol 1991;11:275-6.
14. McDougle CJ, Price LH, Volkmar FR, Goodman WK, Ward-O'Brien D, Nielsen J, Bregman J, Cohen DJ. Clomipramine in autism: preliminary evidence of efficacy. J Am Acad Child Adolesc Psychiatry 1992;31:746-50.
15. Gordon CT, Rapoport JL, Hamburger SD, State RC, Mannheim GB. Differential response of seven subjects with autistic disorder to clomipramine and desipramine. Am J Psychiatry 1992;149: 363-6.
16. Gordon CT, State RC, Nelson JE, Hamburger SD, Rapoport JL. A double-blind comparison of clomipramine, desipramine, and placebo in the treatment of autistic disorder. Arch Gen Psychiatry 1993;50:441-7.
17. Brasic JR, Barnett JY, Kaplan D, Sheitman BB, Aisemberg P, Lafargue RT, Kowalik S, Clark A, Tsaltas MO, Young JG. Clomipramine ameliorates adventitious movements and compulsions in prepubertal boys with autistic disorder and severe mental retardation. Neurology 1994;44:1309-12.
18. Sanchez LE, Campbell M, Small AM, Cueva JE, Armenteros JL, Adams PB. A pilot study of clomipramine in young autistic children. J Am Acad Child Adolesc Psychiatry 1996;35:537-44.
19. Brodkin ES, McDougle CJ, Naylor ST, Cohen DJ, Price LH. Clomipramine in adults with pervasive developmental disorders: a prospective open-label investigation. J Child Adolesc Psychopharmacol 1997;7:109-21.
20. Brasic JR, Barnett JY, Sheitman BB, Tsaltas MO. Adverse effects of clomipramine. J Am Acad Child Adolesc Psychiatry 1997; 36:1165-6.
21. Cook EH Jr, Rowlett R, Jaselskis C, Leventhal BL. Fluoxetine treatment of children and adults with autistic disorder and mental retardation. J Am Acad Child Adolesc Psychiatry 1992;31: 739-45.
22. McDougle CJ, Brodkin ES, Naylor ST, Carlson DC, Cohen DJ, Price LH. Sertraline in adults with pervasive developmental disorders: a prospective open-label investigation. J Clin Psychopharmacol 1998;18:62-6.
23. Snead RW, Boon F, Presberg J. Paroxetine for self-injurious behavior [letter]. J Am Acad Child Adolesc Psychiatry 1994:33: 909-10.
24. McDougle CJ, Naylor ST, Cohen DJ, Volkmar FR, Heninger GR, Price LH. A double-blind, placebo-controlled study of fluvoxamine in adults with autistic disorder. Arch Gen Psychiatry 1996;53:1001-8.
25. Campbell M, Anderson LT, Meier M, Cohen IL, Small AM, Samit C, Sachar EJ. A comparison of haloperidol and behavior therapy and their interaction in autistic children. J Am Acad Child Adolesc Psychiatry 1978;17:640-55.
26. Naruse H, Nagahata M, Nakane Y, Shirahashi K, Takesada M, Yamazaki K. A multi-center double-blind trial of pimozide (Orap), haloperidol and placebo in children with behavior disorders, using cross-over design. Acta Paedopsychiatrica 1982; 48:173-84.
27. Campbell M, Armenteros JL, Malone RP, Adams PB, Eisenberg ZW, Overall JE. Neuroleptic-related dyskinesias in autistic children: a prospective, longitudinal study. J Am Acad Child Adolesc Psychiatry 1997;36:835-43.
28. Potenza MN, McDougle CJ. Potential of atypical antipsychotics in the treatment of nonpsychotic disorders. CNS Drugs 1998;9:1-21.
29. Meltzer HY. Atypical antipsychotic drugs. In: Bloom FE, Kupfer DJ, eds. Psychopharmacology: the fourth generation of progress. New York: Raven Press, 1995:1277-86.
30. Leysen JE, Janssen PMF, Megens AAHP, Schotte A. Risperidone: a novel antipsychotic with balanced serotonin-dopamine antagonism, receptor occupancy profile, and pharmacologic activity. J Clin Psychiatry 1994;55:5-12.
31. Kapur S, Remington G. Serotonin-dopamine interaction and its relevance to schizophrenia. Am J Psychiatry 1996;153:466-76.
32. Zuddas A, Ledda MG, Fratta A, Muglia P, Cianchetti C. Clinical effects of clozapine on autistic disorder [letter]. Am J Psychiatry 1996;153:738.
33. Purdon SE, Lit W, Labelle A, Jones BD. Risperidone in the treatment of pervasive developmental disorder. Can J Psychiatry 1994;39:400-5.
34. McDougle CJ, Brodkin ES, Yeung PP, Naylor ST, Cohen DJ, Price LH. Risperidone in adults with autism or pervasive developmental disorder. J Child Adolesc Psychopharmacol 1995;5:273-82.
35. Simeon JG, Carrey NJ, Wiggins DM, Milin RP, Hosendocus SN. Risperidone effects in treatment-resistant adolescents: preliminary case report. J Child Adolesc Psychopharmacol 1995;5: 69-79.
36. Fisman S, Steele M, Short J, Byrne T, Lavallee C. Case study: anorexia nervosa and autistic disorder in an adolescent girl. J Am Acad Child Adolesc Psychiatry 1996;35:937-40.
37. Fisman S, Steele M. Use of risperidone in pervasive developmental disorders: a case series. J Child Adolesc Psychopharmacol 1996;6:177-90.
38. Demb HB. Risperidone in young children with pervasive developmental disorders and other developmental disabilities [letter]. J Child Adolesc Psychopharmacol 1996;6:79-80.
39. Hardan A, Johnson K, Johnson C, Hrecznyj B. Case study: risperidone treatment of children and adolescents with developmental disorders. J Am Acad Child Adolesc Psychiatry 1996;35:1551-6.
40. Lott RS, Kerrick JM, Cohen SA. Clinical and economic aspects of risperidone treatment in adults with mental retardation and behavioral disturbance. Psychopharmacol Bull 1994;32:721-9.
41. McDougle CJ, Holmes JP, Bronson MR, Anderson GM, Volkmar FR, Price LH, Cohen DJ. Risperidone treatment of children and adolescents with pervasive developmental disorders: a prospective open-label study. J Am Acad Child Adolesc Psychiatry 1997; 36:685-93.
42. Rubin M. Use of atypical antipsychotics in children with mental retardation, autism, and other developmental disabilities. Psychiatr Ann 1997;27:219-21.
43. Horrigan JP, Barnhill LJ. Risperidone and explosive aggressive autism. J Autism Dev Disord 1997;27:313-23.
44. Frischauf E. Drug therapy in autism [letter]. J Am Acad Child Adolesc Psychiatry 1997;36:577.
45. McDougle CJ, Holmes JP, Carlson DC, Pelton GH, Cohen D, Price LH. A double-blind, placebo-controlled study of risperidone in adults with autistic disorder and other pervasive developmental disorders. Arch Gen Psychiatry 1998;55:633-41.
46. Horrigan JP, Barnhill LJ, Courvoisie HE. Olanzapine in PDD. J Am Acad Child Adolesc Psychiatry 1997;36:1166-7.
47. Le Couteur A, Rutter M, Lord C, Rios P, Robertson S, Holdgrafer M, McLennan J. Autism diagnostic interview: A standardized investigator-based instrument. J Autism Dev Disord 1989;19:363-87.
48. Lord C, Rutter M, Goode S, Heemsbergen J, Jordan H, Mawhood L, Schopler E. Autism diagnostic observation schedule: a standardized observation of communicative and social behavior. J Autism Dev Disord 1989;19:185-212.
49. Guy W. ECDEU assessment manual for psychopharmacology [publication no. 76-338]. Washington, DC: US Department of Health, Education, and Welfare, 1976.
50. Goodman WK, Price LH, Rasmussen SA, Mazure C, Fleischmann R, Hill C, Heninger GR, Charney DS. The Yale-Brown Obsessive Compulsive Scale (Y-BOCS). Part I. Development, use, and reliability. Arch Gen Psychiatry 1989;46:1006-11.
51. Goodman WK, Price LH, Rasmussen SA, Mazure C, Delgado P, Heninger GR, Charney DS. The Yale-Brown Obsessive Compulsive Scale (Y-BOCS). Part II. Validity. Arch Gen Psychiatry 1989;46:1012-6.
52. Freeman BJ, Ritvo ER, Yokota A, Ritvo A. A scale for rating symptoms of patients with the syndrome of autism in real life settings. J Am Acad Child Adolesc Psychiatry 1986;25:130-6.
53. Wechsler D. Manual for the Wechsler Adult Intelligence Scale -Revised. San Antonio, TX: The Psychological Corporation, 1981.
54. Wechsler D. Manual for the Wechsler Intelligence Scale for Children. 3rd ed. San Antonio, TX: The Psychological Corporation, 1992.
55. Leiter RG. Leiter International Performance Scale. Chicago, IL: Stoelting Co., 1948.
56. Sparrow SS, Balla DA, Cicchetti DV. Vineland Adaptive Behavior Scales (a revision of the Vineland Social Maturity Scale by Edgar A. Doll). Circle Pines, MN: American Guidance Service, 1984.
57. McDougle CJ, Naylor ST, Goodman WK, Volkmar FR, Cohen DJ, Price LH. Acute tryptophan depletion in autistic disorder: a controlled case study. Biol Psychiatry 1993;33:547-50.
58. Chien C, Jung K, Ross-Townsend A, Stearns B. The measurement of persistent dyskinesia by piezoelectric recording and clinical rating scales. Psychopharmacol Bull 1977;13:34-6.
59. Tollefson GD, Beasley CM Jr, Tran PV, Street JS, Krueger JA, Tamura RN, Graffeo KA, Thieme ME. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. Am J Psychiatry 1997;154:457-65.
60. Locascio JJ, Malone RP, Small AM, Kafantaris V, Ernst M, Lynch NS, Overall JE, Campbell M. Factors related to haloperidol response and dyskinesias in autistic children. Psychopharmacol Bull 1991;27:119-26.
61. Tran PV, Hamilton SH, Kuntz AJ, Potvin JH, Andersen SW, Beasley C, Tollefson GD. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. J Clin Psychopharmacol 1997;17:407-18.
62. Bymaster FP, Calligaro DO, Falcone JF, Marsh RD, Moore NA, Tye NC, Seeman P, Wong DT. Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology 1996;14:87-96.
63. Roth BL, Craigo SC, Choudhary MS, Uluer A, Monsma FJ, Shen Y, Meltzer HY, Sibley DR. Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors. J Pharmacol Exp Ther 1994;268:1403-10.
64. Paclt I, Hellerova P. Ritanserin u autistickych det i [Ritanserin in autistic children]. Cesk Psychiatr 1993;89:85-6.
65. Monsma FJ, Shen Y, Ward RP, Hamblin MW, Sibley DR. Cloning and expression of a novel serotonin receptor with high affinity for tricyclic psychotropic drugs. Mol Pharmacol 1993;43:320-7.
66. Shen Y, Monsma FJ, Metcalf MA, Jose PA, Hamblin MW, Sibley DR. Molecular cloning and expression of a 5-hydroxytryptamine-7 serotonin receptor subtype. J Biol Chem 1993;268:18200-4.
67. 3H-5-hydroxytryptamine binding site subtype in bovine brain membranes. J Neurosci 1987;7:894-903.
68. Zald DH, Kim SW. Anatomy and function of the orbital frontal cortex, I: anatomy, neurocircuitry, and obsessive-compulsive disorder. J Neuropsychiatry Clin Neurosci 1996;8:125-38.
69. Cottraux J, Gerard D, Cinotti L, Froment JC, Deiber MP, Le Bars D, Galy G, Millet P, Labbe C, Lavenne F, Bouvard M, Mauguiere F. A controlled positron emission tomography study of obsessive and neutral auditory stimulation in obsessive-compulsive disorder with checking rituals. Psychiatry Res 1996;60:101-12.
70. Schwartz JM, Stoessel PW, Baxter LR Jr, Martin KM, Phelps ME. Systematic changes in cerebral glucose metabolic rate after successful behavior modification treatment of obsessive-compulsive disorder. Arch Gen Psychiatry 1996;53:109-13.